| Title |
Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics
|
|---|---|
| Published in |
International Journal of Clinical Pharmacy, January 2011
|
| DOI | 10.1007/s11096-010-9454-1 |
| Pubmed ID | |
| Authors |
D. A. Perwitasari, Hans Gelderblom, Jarir Atthobari, Mustofa Mustofa, Iwan Dwiprahasto, Johan W. R. Nortier, Henk-Jan Guchelaar |
| Abstract |
Nausea and vomiting are the most distressful side effects of cytotoxic drugs in cancer patients. Antiemetics are commonly used to reduce these side effects. However, the current antiemetic efficacy is about 70-80% in patients treated with highly-emetogenic cytotoxic drugs. One of the potential factors explaining this suboptimal response is variability in genes encoding enzymes and proteins which play a role in metabolism, transport and receptors related to antiemetic drugs. Aim of this review was to describe the pharmacology and pharmacogenetic concepts of of antiemetics in oncology. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 137 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Brazil | 1 | <1% |
| Egypt | 1 | <1% |
| Unknown | 134 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 22 | 16% |
| Student > Ph. D. Student | 15 | 11% |
| Student > Master | 14 | 10% |
| Other | 13 | 9% |
| Student > Postgraduate | 10 | 7% |
| Other | 31 | 23% |
| Unknown | 32 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 46 | 34% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 12% |
| Agricultural and Biological Sciences | 11 | 8% |
| Biochemistry, Genetics and Molecular Biology | 6 | 4% |
| Chemistry | 5 | 4% |
| Other | 18 | 13% |
| Unknown | 35 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 June 2020.
All research outputs
#6,414,688
of 22,792,160 outputs
Outputs from International Journal of Clinical Pharmacy
#337
of 1,079 outputs
Outputs of similar age
#47,275
of 182,981 outputs
Outputs of similar age from International Journal of Clinical Pharmacy
#2
of 8 outputs
Altmetric has tracked 22,792,160 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 1,079 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 182,981 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.